ERASMID

Erasca, Inc.

HealthcareBiotechnology
$10.90
$0.01(+9.11%)
52W$1.06
$24.28
Updated May 7, 12:00 AM
RSI33
RS Rating98/99
Beta0.78
Volatility110%
F-Score2/9
Mkt Cap$3.1B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Erasca, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Investors should exercise caution due to high volatility (110% annualized), which requires wider risk management.

Relative Strength
98
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.78
vs S&P 500
DEFENSIVE
52W Position
42%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$15.52
50 SMA > 100 SMA$11.79
100 SMA > 150 SMA$8.73
150 SMA > 200 SMA$6.96

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$16.18-32.63%BELOW
50 SMA$15.52-29.78%BELOW
100 SMA$11.79-7.58%BELOW
150 SMA$8.73+24.80%ABOVE
200 SMA$6.96+56.67%ABOVE

Price Performance

1D+9.1%
1W+19.6%
1M-36.3%
3M-11.3%
6M+386.6%
YTD+203.6%
1Y+7.7%
3Y+56.2%
52-Week Trading Range42% from low
$10.90
52W Low$1.06
52W High$24.28

Technical Indicators

RSI (14)BEARISH
33.2
305070
VCP ScoreCOOL
1/10
Base depth: 142.9%

Risk Profile

Beta
0.78
52W Vol
110%
ATR
$2.56
Max DD (1Y)
-59%

Volume Analysis

Today
6.02M
50D Avg
7.01M
Vol Ratio
0.86x
Liquidity
LIQUID

Earnings Momentum

Q4'24+45%
$-0.11
Q1'25+52%
$-0.11
Q2'25+59%
$-0.12
Q3'25
$-0.11
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth

10 Years:
5 Years:
3 Years:
TTM:+45.78%

Stock Price CAGR

10 Years:-4.59%
5 Years:-8.96%
3 Years:+56.20%
1 Year:+7.72%

Return on Equity

10Y Avg:-78.8%
5Y Avg:-78.8%
3Y Avg:-44.6%
Last Year:-36.7%

Key Metrics

Market Cap$3.1B
Gross Margin
Net Margin
Piotroski F-Score2/9

Frequently Asked Questions

Is ERAS in an uptrend right now?

ERAS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ERAS overbought or oversold?

ERAS's RSI (14) is 33. The stock is in neutral territory, neither overbought nor oversold.

Is ERAS outperforming the market?

ERAS has a Relative Strength (RS) Rating of 98 out of 99. Yes, ERAS is a market leader, outperforming 98% of all stocks over the past 12 months.

Where is ERAS in its 52-week range?

ERAS is trading at $10.90, which is 45% of its 52-week high ($24.28) and 42% above its 52-week low ($1.06).

How volatile is ERAS?

ERAS has a Beta of 0.78 and 52-week volatility of 110%. It's less volatile than the S&P 500 - generally more stable.

Disclaimer: Data is for informational purposes only. May be delayed or contain errors. Past performance does not guarantee future results. This is not financial advice. Always conduct your own research and consult professionals before making investment decisions.